Synthace Raises $35 Million to Expand Access to R&D Technology

In the Lab eNewsletter, Pharmaceutical Technology's In the Lab eNewsletter, December 2021, Volume 16, Issue 12

Synthace has raised $35 million in funding to fuel growth of its life sciences R&D technology.

Synthace, a US-based life sciences software company specializing in automating biology experimentation announced on Nov. 16, 2021, that it has raised $35 million in Series C funding to fuel commercial and go-to-market (GTM) growth for its life sciences R&D technology. The company also plans to expand its senior leadership team in the United States by appointing new vice presidents of marketing and sales.

The raised funding follows the recent release of Synthace’s life sciences R&D cloud, which is a no-code software platform that addresses simplification, speed, and reproducibility for scientists. Launched in August 2021 (1), the software platform removes barriers to innovation, allowing scientists to globally benefit from a significant leap in experimentation capabilities. This, in turn, could accelerate development timelines and allow scientists to perform experiments that may not have been possible for them to conduct before.

According to Synthace in a company press release, seven of the top 10 global pharmaceutical companies have adopted Synthace’s next-gen R&D cloud platform with the aim of fundamentally changing their experimentation process. More companies are currently evaluating the adoption of the platform. Synthace’s automated experimentation solutions will allow customers to run increasingly complex experiments that will automatically generate data and insights. Ultimately, this could result in increased competitiveness and accelerated innovation.

“Synthace’s R&D cloud platform is helping life scientists completely change the way they develop new cures and therapeutics to solve humanity’s most pressing problems,” said Guy Levy-Yurista, CEO of Synthace, in the press release. “But to maximize impact, we need to expand access and reach to customers across the globe—at scale. This investment serves as a strong vote of confidence from world-class investors in the biopharmaceutical and innovation technology industries. With their support, we’ll be able to better deploy human and financial capital to help transform scientific dreams into drugs and alternative food sources.”

“I envisaged an automated platform where our molecular biology and protein purification workflows proceeded end to end with sample tracking and barcoding throughout,” said Tony Keeley, senior protein scientist at Syngenta, a provider of science-based agtech, in the press release. “Working closely with the Synthace team has enabled this to happen.”

"Synthace has been a key partner of Wheeler’s in establishing a digital R&D lab environment. Their automation engineers worked side-by-side with our process scientists to automate multiple end-to-end workflows creating more walkaway time for scientists who can now focus on data analysis, interpretation, planning and communication directly with customers,” said Jesse McCool, co-founder and CEO at Wheeler Bio, a biomanufacturing company specializing in the integration of drug discovery with drug development to accelerate clinical impact, in the press release.

Reference

1. Synthace, “First Ever No-Code Platform Lowers Barriers to Automated Biological Experimentation and Insight Sharing,” Press Release, Aug. 2, 2021.

Source: Synthace